FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients.
Tassi RA, Gambino A, Ardighieri L, Bignotti E, Todeschini P, Romani C, Zanotti L, Bugatti M, Borella F, Katsaros D, Tognon G, Sartori E, Odicino F, Romualdi C, Ravaggi A.
Tassi RA, et al. Among authors: romani c.
Br J Cancer. 2019 Oct;121(7):584-592. doi: 10.1038/s41416-019-0553-z. Epub 2019 Aug 22.
Br J Cancer. 2019.
PMID: 31434988
Free PMC article.